The Study of Combination Use of Melatonin Receptor Agonist for Dose Reduction or Interruptions of Benzodiazepine (BZD) and Non-BZD Hypnotics on Chronic Insomnia

Chronic Insomnia Clinical Trial

— BRED  

Official title:

The Placebo Controlled Randomized Double Blind Multicenter Study to Investigate Effectiveness and Safety of Combination Use of Melatonin Receptor Agonist for Dose Reduction or Interruptions of BZD and Non-BZD Hypnotics on Chronic Insomnia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03461042
• Other study ID #: 293/CR1-003 / TRIPSYCHI1407
• Status: Completed
• Phase: Phase 4
• Start date: February 6, 2018
• Est. completion date: March 16, 2020

Study information

• Verified date: January 2021
• Source: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To investigate effects on combination use of Ramelteon in the dose reduction or interruption process of (non-)BZD hypnotics during the dose reduction or interruption algorithm.

Description:

The hypnotic 'Ramelteon' does not have effect on Gamma Aminobutyric Acid (GABA-A) receptor that relates to the formation of addiction to the BZD or non-BZD hypnotics. Some results of clinical trials has been reported that the dose reduction or interruption of (non-)BZD hypnotics was achieved on combination use of Ramelteon by using its characteristic of the action mechanism with safely and effectively. However, these results have not been confirmed with randomized controlled trials.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 17
• Est. completion date: March 16, 2020
• Est. primary completion date: July 31, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

Subjects meeting Criteria 1 or 2 and Criteria 3 and all subsequent criteria will be

included in the study:

1. Patients diagnosed as chronic insomnia having sleep onset disturbance, and with a duration of the disease of at least 6 months

2. Patients diagnosed with chronic insomnia comorbid with mood disorders (depression or bipolar disorder) can be included to this study if they have remission of mood symptoms.

3. Patients taking (non-)BZD hypnotics (including etizolam at bedtime) at a fixed dose in the following patterns since at least 1 month prior to consent (over 90% of drug

compliance should be confirmed at the time of medical interview):

• Patients taking 2 drugs at the usual dose (1 unit)
• Patients taking 3 drugs at the usual dose (1 unit)
• Patients taking 4 drugs at the usual dose (1 unit)
• Patients taking a drug at 2-fold of the usual dose (2 units)
• Patients taking a drug at 2-fold of the usual dose (2 units) and a drug at the usual dose (1 unit)
• Patients taking a drug at 2-fold of the usual dose (2 units) and 2 drugs at the usual dose (1 unit)
• Patients taking 2 drugs at 2-fold of the usual dose (2 units) Patients whose total dosage are 2~4 units of 1~4 drugs can be also included. But attention needed not to conflict with exclusion criteria 2. ?Dosage cannot exceeded 2 units per 1 drug.
• Patients whose symptoms of insomnia were stabilized, and the investigators determined that the (non-) BZD hypnotics could be reduced or discontinued
• Patients aged 20 years or older at the time of consent
• Patients who are willing to comply with algorithm for dose reduction and discontinuation
• Patients who can understand the content of the study and provide consent to participate in the study in writing on their own will. Exclusion Criteria:

Subjects meeting any of the following criteria will not be included in the study:

• Patients with secondary insomnia
• Patients taking (non-)BZD hypnotics at a dose exceeding 2-fold of the usual dose
• Patients taking barbiturate and non-barbiturate hypnotics and Suvorexant.
• Patients taking hypnotics other than medicinal pharmaceuticals (including Over The Counter (OTC), supplements believed to be effective for insomnia and melatonin )
• Patients taking mianserin hydrochloride, mirtazapine, and trazodone hydrochloride
• Patients taking antipsychotics
• Patients taking anxiolytic or clonazepam at bedtime *Patient taking anxiolytic and/or clonazepam at times except for bed-time will be included in the study. However, dosage and timing of administration can not be changed during the study period.
• Patients who took ramelteon within 1 month prior to the informed consent
• Patients in whom the dose of psychotropics except for the items 2~7 were changed within 1 month prior to the informed consent
• Patients who are comorbid with depression or bipolar disordered and in whom depressive symptoms have not remitted
• Patients in whom frequency in Q9 of PHQ "thoughts that you would be better off dead or thoughts of hurting yourself in some way" is "more than half the days (in the past 2 weeks)" or the total score is 10 or higher
• Patients with dementia, schizophrenia, drug dependence and alcoholic
• Patients with liver/kidney disorder, female subjects who are pregnant or in breast-feeding, and malignant neoplasm
• Night workers
• Patients meeting contraindications for ramelteon
• Other patients judged ineligible for participation in the study by the investigator

Related Conditions & MeSH terms

• Chronic Insomnia
• Sleep Initiation and Maintenance Disorders

Intervention

Drug:
• Ramelteon 8mg
Ramelteon 8mg once daily before bedtime for 12 weeks since informed consent
• Placebo
Placebo capsule once daily before bedtime for 12 weeks since informed consent

Locations

Country	Name	City	State
Japan	Yoyogi Sleep Disorder Clinic, Foundation of Sleep and Health Science	Shibuya-ku	Tokyo

Sponsors (2)

Lead Sponsor	Collaborator
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan	Yoyogi Sleep Disorder Clinic, Foundation of Sleep and Health Science

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The achievement ratio of the 50% dose reduction of (non-)BZD hypnotics (Diazepam conversion value) at 12weeks or withdrawal without any deterioration of insomnia symptoms.	Evaluate the achievement ratio of the 50% or more of dose reduction by Participant's diary	12 weeks
Primary	The rate of subjects who achieved more than 50% dose reduction of (non-)BZD hypnotics (Diazepam conversion value) at 12 weeks or withdrawal since informed consent.	The rate of subjects who achieved more than 50% of dose reduction (Diazepam conversion value) will be assessed by Participant's diary	12 weeks
Secondary	The achievement ratio of the 50% dose reduction (Diazepam conversion value) at 4weeks and 8weeks	The rate of subjects who achieved more than 50% dose reduction (Diazepam conversion value) will be assessed by Participant's diary	at 4 weeks and 8weeks
Secondary	The average of the dose reduction rate at 4weeks, 8weeks and 12weeks	The average of the dose reduction rate will be assessed by Participant's diary	at 4 weeks, 8weeks and 12 weeks
Secondary	The achievement ratio of the 100% dose reduction at 12weeks or withdrawal	The achievement ratio of the 100% dose reduction will be assessed by Participant's diary	12 weeks
Secondary	The variation in total score of Pittsburg Sleep Quality Index (PSQI) at 4weeks, 8weeks and 12weeks	The variation in total score of PSQI will be assessed by the PSQI value sets sets at week 0, 4, 8 and 12. (The range of total score is 0-21. Higher scores represent worse tendency of the symptoms.)	at 0, 4, 8 and 12 weeks
Secondary	The variation in total score of Athens Insomnia Scale (AIS) at 4weeks, 8weeks and 12weeks	The variation in total score of AIS will be assessed by the AIS value sets at week 0, 4, 8 and 12. (The range of total score is 0-24. Higher scores represent worse tendency of the symptoms.)	at 0, 4, 8 and 12 weeks
Secondary	The variation in Patient health questionnaire (PHQ-9) score at 4weeks, 8weeks and 12weeks	The variation in PHQ-9 score will be assessed by the PHQ-9 value sets at week 0, 4, 8 and 12. (The range of total score is 0-27. Higher scores represent worse tendency of the symptoms.)	at 0, 4, 8 and 12 weeks
Secondary	Guide to the use of the clinical withdrawal assessment scale for benzodiazepines (CIWA-B) score at 4weeks, 8weeks and 12weeks	The variation in CIWA-B (Guide to the use of the clinical withdrawal assessment scale for benzodiazepines) score will be assessed by the CIWA-B value sets at week 4, 8 and 12. (The range of total score is 0-80. Higher scores represent worse tendency of the symptoms.)	at 4, 8 and 12 weeks
Secondary	Patient global impression of therapy (PGI) score at 12weeks or withdrawal	PGI(Patient global impression of therapy) score will be assessed by the PGI value sets at 12weeks or withdrawal. (The range of total score is 0-21. Higher scores represent worse tendency of the symptoms.)	12 weeks
Secondary	The variation in Ben-dep(Benzodiazepine Dependence Self-Report Questionnaire) score at 12weeks or withdrawal	The variation in Ben-dep score will be assessed by the Ben-dep value sets at 0 and 12weeks or withdrawal. (The range of total score is 0-100. Higher scores represent worse tendency of the symptoms.)	at 0 and 12 weeks
Secondary	Adverse Events	Adverse Events will be determined by the latest version of MedDRA/J (Medical Dictionary for Regulatory Activities/J).	12 weeks